### Tests Ordered

- **Aggressive B Cell Lymphoma**; FISH DNA Probe X6; FISH Analyze 100−300 cells X3; Chromosomes Leuk/Lymph

### Tests

<table>
<thead>
<tr>
<th>Test</th>
<th>Result</th>
<th>Flag</th>
<th>Units</th>
<th>Reference Interval</th>
<th>Lab</th>
</tr>
</thead>
</table>

#### Aggressive B Cell Lymphoma

- **Cells Counted**
  - Comment: 100/PROBE
  - Comment: 01

- **Cells Analyzed**
  - Comment: 100/PROBE
  - Comment: 01

- **FISH Result**
  - Comment: NORMAL: NO REARRANGEMENT OF BCL6, MYC, OR BCL2 OBSERVED
  - Interpretation Comment: NORMAL: NO REARRANGEMENT OF BCL6, MYC, OR BCL2 OBSERVED

### Report

The fluorescence in situ hybridization (FISH) study targeting BCL6, MYC, and BCL2 was normal. These genes are associated with BCL6 associated lymphoid disorders, Burkitt lymphoma, and Follicular lymphoma.

**SPECIFIC PROBE RESULTS:**

- **BCL6:** NORMAL nuc ish 3q27(BCL6x2)[100]
  - MYC: NORMAL nuc ish 8q24(MYCx2)[100]
  - BCL2: NORMAL nuc ish 18q21(BCL2x2)[100]

Chromosome analysis should be considered to identify clonal alterations not targeted by the FISH probes ordered. FISH results should be interpreted within the context of a full hematopathology evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration.
**Sample Report, 510344**

<table>
<thead>
<tr>
<th>Account Number</th>
<th>Patient ID</th>
<th>Control Number</th>
<th>Date and Time Collected</th>
<th>Date Reported</th>
<th>Sex</th>
<th>Age(Y/M/D)</th>
<th>Date of Birth</th>
</tr>
</thead>
<tbody>
<tr>
<td>90000999</td>
<td></td>
<td></td>
<td>09/13/16 00:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Patient Name**

**Specimen Number**

<p>| | | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>257-225-9017-0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Tests**

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Comment:</th>
<th>Flag</th>
<th>Units</th>
<th>Reference</th>
<th>Interval</th>
<th>Lab</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLOOD</td>
<td></td>
<td>01</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Director Review:**

Rachel Burnside, PhD, FACMG

**Branch:** 800-222-7566

**Lab:** 800-735-4087
LCLS Specimen Number: 257-225-9017-0
Client/Sending Facility: LabCorp Test Master
Test Account
3060 South Church Street
Burlington, NC 27215
Ph: (336)436-8645
POE-00

Patient Name: SAMPLE REPORT, 510344
Account Number: 90000999
Date of Birth: 06/12/1985
Ordering Physician: BLOOD
Gender: F
Client Reference: Date Collected: 09/13/2016
Patient ID: Date Received: 09/14/2016
Lab Number: YU16-72770 F
Date Reported: 09/14/2016

Indications: Test: Aggressive B Cell Lymphoma

Cells Counted: 100/PROBE
Cells Analyzed: 100/PROBE

FISH RESULT: NORMAL: NO REARRANGEMENT OF BCL6, MYC, OR BCL2 OBSERVED

INTERPRETATION:

The fluorescence in situ hybridization (FISH) study targeting BCL6, MYC, and BCL2 was normal. These genes are associated with BCL6 associated lymphoid disorders, Burkitt lymphoma, and Follicular lymphoma.

SPECIFIC PROBE RESULTS:

BCL6: NORMAL nuc ish 3q27(BCL6x2)[100]
MYC: NORMAL nuc ish 8q24(MYCx2)[100]
BCL2: NORMAL nuc ish 18q21(BCL2x2)[100]

Chromosome analysis should be considered to identify clonal alterations not targeted by the FISH probes ordered. FISH results should be interpreted within the context of a full hematopathology evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration.
LCLS Specimen Number: 257-225-9017-0
Patient Name: SAMPLE REPORT, 510344
Date of Birth: 06/12/1985
Gender: F
Patient ID: SAMPLE REPORT, 510344
Lab Number: YU16-72770 F

Account Number: 90000999
Ordering Physician:
Specimen Type: BLOOD
Client Reference:
Date Collected: 09/13/2016
Date Received: 09/14/2016

Rachel Burnside, PhD, FACMG
Board Certified Cytogeneticist

Arundhati Chatterjee, MD
Medical Director

Peter Papenhausen, PhD
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings,
1904 TW Alexander Drive, RTP, NC, 27709-0153 (800) 345-4363

Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD. Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information protected by state and federal law.
**Tests Ordered**

Aggressive B Cell Lymphoma; FISH DNA Probe X6; FISH Analyze 100–300 cells X3; Chromosomes Leuk/Lymph

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aggressive B Cell Lymphoma</td>
<td>Comment:</td>
<td>01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cells Counted</td>
<td></td>
<td>100/PROBE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cells Analyzed</td>
<td></td>
<td>100/PROBE</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FISH Result</td>
<td>Comment:</td>
<td>01</td>
<td>01</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55.0–75.0% OF NUCLEI POSITIVE FOR REARRANGEMENT OF BCL2, BCL6, AND MYC</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interpretation</td>
<td>Comment:</td>
<td>01</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ABNORMAL RESULT--TRIPLE-HIT LYMPHOMA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The fluorescence in situ hybridization (FISH) analysis was positive for rearrangement of BCL2, BCL6, and MYC. A subset of B-cell lymphomas are double-hit or triple-hit lymphomas characterized by two or three recurrent chromosome translocations; MYC/8q24 loci, usually in combination with the t(14;18)(q32;q21) involving BCL2 gene or/and BCL6/3q27 chromosomal translocations. Double-hit or triple-hit B-cell lymphomas have clinical features intermediate between DLBCL and Burkitt lymphoma and are usually associated with poor prognosis.

Specific FISH results:

- **BCL2**: ABNORMAL nuc ish 18q21(BCL2x2)(5'BCL2 sep 3'BCL2x1)(55/100)

- **MYC**: ABNORMAL nuc ish 8q24(CMYCx2)(5'CMYC sep 3'CMYCx1)(75/100)

- **BCL6**: ABNORMAL nuc ish 3q27(BCL6x2)(5'BCL6 sep 3'BCL6x1)(58/100)

FISH results should be interpreted within the context of
histology, IHC, and a pathological evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.

<table>
<thead>
<tr>
<th>Specimen Type</th>
<th>Comment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>BLOOD</td>
<td>01</td>
</tr>
</tbody>
</table>

Director Review:

Rachel Burnside, PhD, FACMG

---

For inquiries, the physician may contact Branch: 800−222−7566  Lab: 800−735−4087
LCLS Specimen Number: 257-225-9018-0

Patient Name: SAMPLE REPORT, 510344

Date of Birth: 06/12/1985

Gender: F

Patient ID: YU16-72771

Lab Number: YU16-72771   F

Indications: Aggressive B Cell Lymphoma

Test: Aggressive B Cell Lymphoma

Cells Counted: 100/PROBE

Cells Analyzed: 100/PROBE

FISH RESULT: 55.0–75.0% OF NUCLEI POSITIVE FOR REARRANGEMENT OF BCL2, BCL6, AND MYC

INTERPRETATION: ABNORMAL RESULT--TRIPLE-HIT LYMPHOMA

The fluorescence in situ hybridization (FISH) analysis was positive for rearrangement of BCL2, BCL6 and MYC. A subset of B-cell lymphomas are double-hit or triple-hit lymphomas characterized by two or three recurrent chromosome translocations; MYC/8q24 loci, usually in combination with the t(14;18)(q32;q21) involving BCL2 gene or/and BCL6/3q27 chromosomal translocations. Double-hit or triple-hit B-cell lymphomas have clinical features intermediate between DLBCL and Burkitt lymphoma and are usually associated with poor prognosis.

Specific FISH results:

BCL2: ABNORMAL nuc ish 18q21(BCL2x2) (5'BCL2 sep 3'BCL2x1)[55/100]

MYC: ABNORMAL nuc ish 8q24(CMYCx2) (5'CMYC sep 3'CMYCx1)[75/100]

BCL6: ABNORMAL nuc ish 3q27(BCL6x2) (5'BCL6 sep 3'BCL6x1)[58/100]

FISH results should be interpreted within the context of histology, IHC, and a pathological evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.
Client/Sending Facility:
LabCorp Test Master
Test Account
3060 South Church Street
Burlington, NC  27215
Ph: (336)436-8645
POE-00

LCLS Specimen Number: 257-225-9018-0
Account Number: 90000999
Patient Name: SAMPLE REPORT, 510344
Ordering Physician: 
Date of Birth: 06/12/1985
Specimen Type: BLOOD
Gender: F
Client Reference: 
Patient ID: 
Date Collected: 09/13/2016
Lab Number: YU16-72771 F
Date Received: 09/14/2016

Rachel Burnside, PhD, FACMG
Board Certified Cytogeneticist

Arundhati Chatterjee, MD
Medical Director

Peter Papenhausen, PhD
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings,
1904 TW Alexander Drive, RTP, NC, 27709-0153 (800) 345-4363

Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD.

Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information protected by state and federal law.